ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy company, has announced a partnership with BioView, a developer and marketer of automated cell imaging and analysis solutions, to create a circulating tumour cell (CTC) HER2 assay for breast cancer.
The test will utilise ANGLE's FDA-cleared Parsortix PC1 Clinical System and BioView's automated microscopy systems and software, and is expected to generate around £1.2mln in revenues for the London-listed group.
The partnership aims to capitalise on the growing demand for quantitative CTC-based HER2 detection assays for the regular stratification of patient populations.
Andrew Newland, ANGLE's founder and CEO, said: "The changing breast cancer treatment landscape has created a major commercial opportunity for a CTC-based HER2 assay allowing repeat testing and longitudinal monitoring of patients to personalise cancer care."